Ranbaxy files additional Anti-Retroviral (ARV) agents with the World Health Organization

Ranbaxy Laboratories Limited (RLL) announced today that the Company has made two additional filings of its Anti-Retroviral (ARV) agents with the World Health Organization (WHO) for its approval, taking the total number of Ranbaxy ARV filings submitted with the WHO to five.

At the same time, Ranbaxy has filed one more ARV with the U.S. FDA under its expedited review process for the President's Emergency Program for Aids Relief (PEPFAR), thus taking the total number of ARV filings with the FDA to four.

Speaking on the development, Dr. Brian W. Tempest, CEO and Managing Director of RLL, said, "Ranbaxy remains committed towards refiling its ARVs with the WHO and the U.S. FDA, under the PEPFAR Program. By this summer, we expect most of our range of HIV medicines to be filed with WHO and U.S. FDA. This is yet another step in making these quality medicines available widely in countries that urgently need them."

Ranbaxy is committed to making affordable, bio-equivalent ARVs accessible to HIV/AIDS patients throughout the world, particularly to those who might not otherwise be able to access therapy.

HIV/AIDS is a serious pandemic that now infects some 40 million people around the globe. More than 20 million individuals have so far succumbed to this devastating disease.

Ranbaxy Inc., based in Princeton, New Jersey, is a wholly owned subsidiary of Ranbaxy Laboratories Limited ("RLL"), India's largest pharmaceutical company.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, manufactures and markets brand and generic pharmaceuticals and Active Pharmaceutical Ingredients. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. Ranbaxy's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies" resulting in a number of products under development. The Company is selling its products in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 44 countries and manufacturing operations in 7 countries.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
An automated bioinformatics pipeline to monitor HIV data in real-time